Data GLP-1 for Adults Q1 2026 Quarterly rates per 100,000 of patients receiving clinical care being prescribed, dispensed, or reporting that they started a GLP-1 medication
45% for SGLT2i and 57% for DPP4i), and more likely to be obese (72% vs
This rapid adoption through novel care delivery models underscores the urgent need for robust safety surveillance and comparative effectiveness research, including ones specifically focused on semaglutide
Notably, a recent meta-analysis of cohort studies revealed that dipeptidyl peptidase-4 inhibitors (DPP-4i) can significantly improve cognitive functions in patients with type-2 diabetes compared to other classes of glucose-lowering agents (i.e., sulfonylurea and metformin) [4]
[PubMed] [Google Scholar] 79.Pitts NB, Zero DT, Marsh PD, et al
For practices operating at scale, the metabolic health EMR workflow includes templated diabetes review sections that prompt clinicians to document all active antidiabetic agents, confirm therapy duration, and tag insulin use as ongoing rather than situational
